These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 18332082)

  • 1. Identification and characterization of potent CYP2B6 inhibitors in Woohwangcheongsimwon suspension, an herbal preparation used in the treatment and prevention of apoplexy in Korea and China.
    Kim H; Kim KB; Ku HY; Park SJ; Choi H; Moon JK; Park BS; Kim JH; Yea SS; Lee CH; Lee HS; Shin JG; Liu KH
    Drug Metab Dispos; 2008 Jun; 36(6):1010-5. PubMed ID: 18332082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects.
    Kim H; Bae SK; Park SJ; Shim EJ; Kim HS; Shon JH; Liu KH; Shin JG
    Br J Clin Pharmacol; 2010 Jul; 70(1):126-31. PubMed ID: 20642555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
    Turpeinen M; Nieminen R; Juntunen T; Taavitsainen P; Raunio H; Pelkonen O
    Drug Metab Dispos; 2004 Jun; 32(6):626-31. PubMed ID: 15155554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity.
    Seo KA; Kim H; Ku HY; Ahn HJ; Park SJ; Bae SK; Shin JG; Liu KH
    Chem Biol Interact; 2008 Aug; 174(3):141-6. PubMed ID: 18611395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols.
    Lau AJ; Chang TK
    Drug Metab Dispos; 2009 Sep; 37(9):1931-7. PubMed ID: 19487249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
    Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
    Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.
    Richter T; Schwab M; Eichelbaum M; Zanger UM
    Biochem Pharmacol; 2005 Feb; 69(3):517-24. PubMed ID: 15652242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
    Richter T; Mürdter TE; Heinkele G; Pleiss J; Tatzel S; Schwab M; Eichelbaum M; Zanger UM
    J Pharmacol Exp Ther; 2004 Jan; 308(1):189-97. PubMed ID: 14563790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
    Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
    Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes.
    Bae SK; Cao S; Seo KA; Kim H; Kim MJ; Shon JH; Liu KH; Zhou HH; Shin JG
    Drug Metab Dispos; 2008 Aug; 36(8):1679-88. PubMed ID: 18474675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
    Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
    Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of CYP2B6 component of 7-ethoxy-4-trifluoromethylcoumarin O-deethylation activity in human liver microsomes.
    Chang TK; Crespi CL; Waxman DJ
    Methods Mol Biol; 2006; 320():97-102. PubMed ID: 16719378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.
    Nishiya Y; Hagihara K; Ito T; Tajima M; Miura S; Kurihara A; Farid NA; Ikeda T
    Drug Metab Dispos; 2009 Mar; 37(3):589-93. PubMed ID: 19047469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.
    Coles R; Kharasch ED
    Pharm Res; 2008 Jun; 25(6):1405-11. PubMed ID: 18219560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.
    Sridar C; Kenaan C; Hollenberg PF
    Drug Metab Dispos; 2012 Dec; 40(12):2256-66. PubMed ID: 22936314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting.
    O'Donnell CJ; Grime K; Courtney P; Slee D; Riley RJ
    Drug Metab Dispos; 2007 Mar; 35(3):381-5. PubMed ID: 17142561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes.
    Yanagihara Y; Kariya S; Ohtani M; Uchino K; Aoyama T; Yamamura Y; Iga T
    Drug Metab Dispos; 2001 Jun; 29(6):887-90. PubMed ID: 11353758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human liver CYP2B6-catalyzed hydroxylation of RP 73401.
    Stevens JC; White RB; Hsu SH; Martinet M
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1389-95. PubMed ID: 9316851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of bioflavonoids on hepatic P450 activities.
    Obermeier MT; White RE; Yang CS
    Xenobiotica; 1995 Jun; 25(6):575-84. PubMed ID: 7483658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms.
    Harleton E; Webster M; Bumpus NN; Kent UM; Rae JM; Hollenberg PF
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1011-9. PubMed ID: 15121764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.